Key result
Dapagliflozin linked to ~410 pg/mL greater NT-proBNP reduction vs empagliflozin in AF and HF.
Why the study?
Does dapagliflozin produce a greater early reduction in NT-proBNP and estimated plasma volume compared to empagliflozin in adults with atrial fibrillation and heart failure?
Cohort (n=910)
No
Does dapagliflozin produce a greater early reduction in NT-proBNP and estimated plasma volume compared to empagliflozin in adults with atrial fibrillation and heart failure?
Answers are grounded in this paper and cite their sources.
In patients with concurrent heart failure and atrial fibrillation, dapagliflozin demonstrated a more pronounced early reduction in NT-proBNP and estimated plasma volume at 6 months compared to empagliflozin, although differences attenuated by 12 months and hospitalization rates were similar.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Zeljković et al. (2026) conducted a cohort in Atrial fibrillation and heart failure (n=910). Dapagliflozin vs. Empagliflozin was evaluated on Change in NT-proBNP (ΔNT-proBNP, pg/mL) and change in estimated plasma volume by Duarte (ΔePV) from baseline to approximately 6 months (Median difference +410 pg/mL (empagliflozin minus dapagliflozin), 95% CI 115-799, p=0.011). Dapagliflozin achieved greater 6-month reductions in NT-proBNP and estimated plasma volume than empagliflozin in patients with AF and HF.
Synapse has enriched 10 related papers. Consider them for comparative context: